小干扰RNA降脂药物英克司兰在心血管疾病中的研究进展
Small Interfering RNA Lipid-Lowering Drug Inclisiran in Cardiovascular Disease
康雅隆 1齐鸿飞 1葛腾 1彭涛 1余婷 1剧嘉欣 1程草草 1关芳 1余湖斌 1王海芳1
作者信息
- 1. 陕西中医药大学 陕西省及咸阳市中西医结合心血管病防治重点实验室,陕西咸阳 712000
- 折叠
摘要
动脉粥样硬化性心血管疾病(ASCVD)是中国城乡居民死亡的第一位原因.动脉粥样硬化是一种慢性炎症性血管病变,也是ASCVD的病变基础,其主要原因是脂质代谢障碍,故降低低密度脂蛋白胆固醇成为防治ASCVD的重要手段.小干扰RNA是一类新型降血脂药.目前,针对该类药物的循证证据和实践经验较少.首个小干扰RNA降脂药物英克司兰于2023年8月在中国获批上市.现介绍英克司兰治疗动脉粥样硬化的机制、与其他降脂药物合用的情况,以及其安全性和不良反应,以期为此类药物的临床应用提供参考.
Abstract
Atherosclerotic cardiovascular disease(ASCVD)is the first cause of death for urban and rural residents in China.Atherosclerosis is a chronic vascular inflammation and the pathological basis of ASCVD,and its main reason is lipid metabolism disorder.Therefore,reducing low-density lipoprotein cholesterol has become an important approach for the prevention and treatment of ASCVD.Small interfering RNA lipid-lowering drugs are novel lipid-lowering drugs.At present,there is little evidence-based evidence and practical experience for this class of drugs.Inclisiran,the first small interfering RNA lipid-lowering drug,was approved for sale in China in August 2023.In this article,we will review the anti-atherosclerostic mechanisms of inclisiran,its combined application with other lipid-lowering drugs,and the safety and adverse effects,and thus to provide supportive evidence in the future clinical application of more small interfering RNA lipid-lowering drugs.
关键词
心血管疾病/动脉粥样硬化/英克司兰/小干扰RNA/血脂管理Key words
Cardiovascular disease/Atherosclerosis/Inclisiran/Small interfering RNA/Lipid management引用本文复制引用
基金项目
陕西省感染与免疫疾病重点实验室开放课题(2022-ZD-3)
陕西省教育厅专项科研计划(21JK0606)
咸阳市中西医结合防治炎性疾病研究科技创新团队(L2022CXNLTD003)
出版年
2024
NETL
NSTL
万方数据